Athanassios Argiris MD

Oncology•Houston, TX

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Professor of Medicine, University Tex San Antonio

Join to View Full Profile

1321 Upland Dr# 4129Houston, TX 77043

Education & Training

Yale-New Haven Medical CenterFellowship, Medical Oncology, 1999
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1994 - 1997
University of AthensClass of 1990

Certifications & Licensure

OH State Medical License Current
PA State Medical License 2005 - 2026
TX State Medical License 2011 - 2026
IL State Medical License 2000 - 2005
CT State Medical License 1997 - 2000

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Fellow (FACP) American College of Physicians, 2005

Clinical Trials

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx Start of enrollment: 1999 Aug 01
Unknown status
Phase 2
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer Start of enrollment: 1999 Aug 01
Unknown status
Phase 1
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer Start of enrollment: 2002 Nov 19
Completed
Phase 2
Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer Start of enrollment: 2002 Sep 01
Completed
Phase 2
Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Start of enrollment: 2003 May 01
Terminated
Phase 2
Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2003 Jun 01
Completed
Phase 1, Phase 2
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Start of enrollment: 2004 Jun 01
Completed
Phase 2
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer Start of enrollment: 2004 Aug 01
Terminated
Phase 3
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Start of enrollment: 2006 Oct 23
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Start of enrollment: 2006 Oct 01
Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2007 Jun 01
Withdrawn
Phase 2
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC Start of enrollment: 2006 Jun 01
Completed
Phase 2
Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck Start of enrollment: 2007 Nov 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Start of enrollment: 2010 Mar 01
Terminated
Phase 2
Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301 Start of enrollment: 2011 Dec 22
Completed
Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies Start of enrollment: 2012 Jul 01
Withdrawn
Phase 2
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma.
Eric V Mastrolonardo, Kathryn L Nunes, Pablo Llerena, Anastasia Nikitina, Anastasia Sobol
Clinical Cancer Research. 2025-02-03
Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.
Angela E Alnemri, Sruti Tekumalla, Annie E Moroco, Ioannis Vathiotis, Madalina Tuluc
Cancer Medicine. 2024-06-01
3 citations
Effect of preoperative programmed death-1 or programmed death ligand-1 immune check point inhibition on complications after surgery for primary head and neck cancer.
Ramez Philips, Angela Alnemri, Dev Amin, Jena Patel, Michael C Topf
Cancer. 2024-03-15

Lectures

S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell...
2019 ASCO Annual Meeting - 6/1/2019
New Drug, New Setting
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage CancersSeptember 8th, 2021
Northwestern Memorial Hospital Studying Arthritis Drug's Potential in Fighting CancerJuly 3rd, 2003